IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination

Cuprizone inhibits mitochondrial function and induces demyelination in the corpus callosum, which resembles pattern III lesions in multiple sclerosis patients. However, the molecular and cellular mechanism by which cuprizone induces demyelination remains unclear. Interleukin-17 (IL-17) secreted by T...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 32; no. 24; pp. 8284 - 8292
Main Authors Kang, Zizhen, Liu, Liping, Spangler, Roo, Spear, Charles, Wang, Chenhui, Gulen, Muhammet Fatih, Veenstra, Mike, Ouyang, Wenjun, Ransohoff, Richard M, Li, Xiaoxia
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 13.06.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cuprizone inhibits mitochondrial function and induces demyelination in the corpus callosum, which resembles pattern III lesions in multiple sclerosis patients. However, the molecular and cellular mechanism by which cuprizone induces demyelination remains unclear. Interleukin-17 (IL-17) secreted by T helper 17 cells and γδT cells are essential in the development of experimental autoimmune encephalomyelitis. In this study, we examined the importance of IL-17 signaling in cuprizone-induced demyelination. We found that mice deficient in IL-17A, IL-17 receptor C (IL-17RC), and adaptor protein Act1 (of IL-17R) all had reduced demyelination accompanied by lessened microglial and polydendrocyte cellular reactivity compared with that in wild-type mice in response to cuprizone feeding, demonstrating the essential role of IL-17-induced Act1-mediated signaling in cuprizone-induced demyelination. Importantly, specific deletion of Act1 in astrocytes reduced the severity of tissue injury in this model, indicating the critical role of CNS resident cells in the pathogenesis of cuprizone-induced demyelination. In cuprizone-fed mice, IL-17 was produced by CNS CD3(+) T cells, suggesting a source of IL-17 in CNS upon cuprizone treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Z.K., L.L., R.M.R., and X.L. designed research; Z.K., L.L., R.S., C.S., C.W., M.F.G., and M.V. performed research; W.O. contributed unpublished reagents/analytic tools; Z.K., L.L., R.S., R.R., and X.L. analyzed data; Z.K., R.R., and X.L. wrote the paper.
Z.K. and L.L. contributed equally to this work.
ISSN:0270-6474
1529-2401
1529-2401
DOI:10.1523/jneurosci.0841-12.2012